Johnson & Johnson Reports Q2 2023 Results : vimarsana.com

2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of...

Related Keywords

United States , Joaquin Duato , Biosense Webster , Kenvue Inc , Abiomed , Women Health , Company Consumer Health , Librexia Program , Consumer Health Company , Interventional Solutions , Exchange Commission , Johnson , Receptor Antagonist Peptide In Development , Consumer Health , Skin Health Beauty , Johnson Announces Launch Of Kenvue Inc , Roadshow , Chief Executive , Pulmonary Hypertension , Infectious Diseases , General Surgery , Advanced Surgery , Current Reports , Quarterly Reports , Annual Reports , Marks First Approval Worldwide , Abiraterone Acetate Dual Action Tablet , Metastatic Castration Resistant Prostate Cancer , Track Designation , All Three Indications Under Evaluation , Ischemic Stroke , Acute Coronary Syndrome , Atrial Fibrillation , Submits New Drug Application , Investigational Single Tablet Combination Therapy , Pulmonary Arterial Hypertension , Earlier Treatment , Refractory Multiple Myeloma , Reports First Results , Bacillus Calmette Gu , Unresponsive Non Muscle Invasive Bladder Cancer , Severely Active Ulcerative Colitis , Data Published , Latest Advancement , Highlight Scientific Advances , Transform Cancer Care , Showcasing Robust , Differentiated Portfolio , Hematologic Malignancies , Solid Tumors , Demonstrate Potential Benefit , Pregnant Individuals , High Risk , Early Onset Severe Hemolytic Disease , Announces Positive Topline Results , Only Oral , Antagonist Peptide , Moderate To Severe Plaque , Statistically Significant , Clinically Meaningful Improvement , Progression Free Survival , Newly Diagnosed , Mutation Positive Non Small Cell Lung , Johnson Announces Launch , Enters Worldwide Collaboration , License Agreement , Cellular Biomedicine Group , Develop Next Generation , Euro Average Rate , Private Securities Litigation Reform Act , New Consumer Health Company , Annual Report , Note Regarding Forward Looking , Consolidated Statement , Millions Except Per Share Figures , Millions Except Per Share Data , Asset Amortization , Net Earnings , Medical Device Regulation , European Medical Devices Directive , Sales Reconciliation , Before Tax , Income Before Tax , Business Wire , Markets ,